Neuropediatrics 2018; 49(01): 012-017
DOI: 10.1055/s-0037-1608653
Review Article
Georg Thieme Verlag KG Stuttgart · New York

A Systematic Review of the Efficacy of Levetiracetam in Neonatal Seizures

Daryl C. McHugh
1   Department of Neurology and the Neurosciences Institute, Stony Brook University Medical Center, Stony Brook, New York, United States
Shannon Lancaster
1   Department of Neurology and the Neurosciences Institute, Stony Brook University Medical Center, Stony Brook, New York, United States
Louis N. Manganas
1   Department of Neurology and the Neurosciences Institute, Stony Brook University Medical Center, Stony Brook, New York, United States
› Author Affiliations
Further Information

Publication History

12 May 2017

24 September 2017

Publication Date:
27 November 2017 (online)


Objective Seizures are the most common neurological complication in neonatal intensive care units. Phenobarbital (PB) remains the first-line antiepileptic drug (AED) for neonatal seizures despite known neurotoxicity. Levetiracetam (LEV) is a newer AED not approved for neonates. Retrospective and pilot studies have investigated the use of LEV in neonatal seizures. Our objective was to compare the efficacy of LEV to PB in neonatal seizures based upon published data.

Methods We searched PubMed to perform a systematic review. We found no studies of LEV with comparison or control groups; therefore, we utilized data from two randomized controlled trials of PB as our comparison group.

Results Five studies of LEV met all inclusion/exclusion criteria. The pooled sample size for LEV was 102 (48 received primary LEV, 54 received secondary LEV). The pooled sample size for primary PB was 52. Complete or near-complete seizure cessation was achieved as follows: primary LEV 37/48 (77%), secondary LEV 34/54 (63%), and primary PB 24/52 (46%).

Conclusion Our findings suggest that LEV may be at least as or more effective for neonatal seizures as PB. Our review, though limited, is the first to examine LEV efficacy compared with PB in neonates.

  • References

  • 1 Vasudevan C, Levene M. Epidemiology and aetiology of neonatal seizures. Semin Fetal Neonatal Med 2013; 18 (04) 185-191
  • 2 Pisani F, Facini C, Pavlidis E, Spagnoli C, Boylan G. Epilepsy after neonatal seizures: literature review. Eur J Paediatr Neurol 2015; 19 (01) 6-14
  • 3 Rosselli-Austin L, Yanai J. Neuromorphological changes in mouse olfactory bulb after neonatal exposure to phenobarbital. Neurotoxicol Teratol 1989; 11 (03) 227-230
  • 4 Sulzbacher S, Farwell JR, Temkin N, Lu AS, Hirtz DG. Late cognitive effects of early treatment with phenobarbital. Clin Pediatr (Phila) 1999; 38 (07) 387-394
  • 5 Forcelli PA, Janssen MJ, Stamps LA, Sweeney C, Vicini S, Gale K. Therapeutic strategies to avoid long-term adverse outcomes of neonatal antiepileptic drug exposure. Epilepsia 2010; 51 (Suppl. 03) 18-23
  • 6 Maitre NL, Smolinsky C, Slaughter JC, Stark AR. Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. J Perinatol 2013; 33 (11) 841-846
  • 7 van Rooij LG, Hellström-Westas L, de Vries LS. Treatment of neonatal seizures. Semin Fetal Neonatal Med 2013; 18 (04) 209-215
  • 8 Pina-Garza JE, Nordli Jr DR, Rating D, Yang H, Schiemann-Delgado J, Duncan B. ; Levetiracetam N01009 Study Group. Adjunctive Levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia 2009; 50 (05) 1141-1149
  • 9 Aceves J, Khan O, Mungall D. , et al. Efficacy and tolerability of intravenous levetiracetam in childrens. Front Neurol 2013; 4: 120
  • 10 Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA. ; Liverpool Manchester Neurodevelopment Group; UK Epilepsy and Pregnancy Register. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011; 76 (04) 383-389
  • 11 Kim JS, Kondratyev A, Tomita Y, Gale K. Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain. Epilepsia 2007; 48 (Suppl. 05) 19-26
  • 12 Loiacono G, Masci M, Zaccara G, Verrotti A. The treatment of neonatal seizures: focus on Levetiracetam. J Matern Fetal Neonatal Med 2016; 29 (01) 69-74
  • 13 Mruk AL, Garlitz KL, Leung NR. Levetiracetam in neonatal seizures: a review. J Pediatr Pharmacol Ther 2015; 20 (02) 76-89
  • 14 Slaughter LA, Patel AD, Slaughter JL. Pharmacological treatment of neonatal seizures: a systematic review. J Child Neurol 2013; 28 (03) 351-364
  • 15 Moher D, Liberati A, Tetzlaff J, Altman DG. ; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med 2009; 3 (03) e123-e130
  • 16 Booth D, Evans DJ. Anticonvulsants for neonates with seizures. Cochrane Database Syst Rev 2004; (04) CD004218
  • 17 Abend NS, Gutierrez-Colina AM, Monk HM, Dlugos DJ, Clancy RR. Levetiracetam for treatment of neonatal seizures. J Child Neurol 2011; 26 (04) 465-470
  • 18 Khan O, Chang E, Cipriani C, Wright C, Crisp E, Kirmani B. Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol 2011; 44 (04) 265-269
  • 19 Khan O, Cipriani C, Wright C, Crisp E, Kirmani B. Role of intravenous levetiracetam for acute seizure management in preterm neonates. Pediatr Neurol 2013; 49 (05) 340-343
  • 20 Ramantani G, Ikonomidou C, Walter B, Rating D, Dinger J. Levetiracetam: safety and efficacy in neonatal seizures. Eur J Paediatr Neurol 2011; 15 (01) 1-7
  • 21 Rakshasbhuvankar A, Rao S, Kohan R, Simmer K, Nagarajan L. Intravenous levetiracetam for treatment of neonatal seizures. J Clin Neurosci 2013; 20 (08) 1165-1167